Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Regen BioPharma (RGBPP) over the last 11 years, with Q4 2025 value amounting to $4578.0.

  • Regen BioPharma's Cash & Current Investments fell 7437.88% to $4578.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4578.0, marking a year-over-year decrease of 7437.88%. This contributed to the annual value of $69555.0 for FY2025, which is 27701.23% up from last year.
  • Latest data reveals that Regen BioPharma reported Cash & Current Investments of $4578.0 as of Q4 2025, which was down 7437.88% from $69555.0 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Cash & Current Investments registered a high of $727162.0 during Q3 2021, and its lowest value of $692.0 during Q2 2023.
  • Moreover, its 5-year median value for Cash & Current Investments was $69555.0 (2025), whereas its average is $133400.9.
  • As far as peak fluctuations go, Regen BioPharma's Cash & Current Investments tumbled by 9937.65% in 2023, and later soared by 883757.23% in 2024.
  • Quarter analysis of 5 years shows Regen BioPharma's Cash & Current Investments stood at $353492.0 in 2021, then plummeted by 88.47% to $40741.0 in 2022, then surged by 205.58% to $124497.0 in 2023, then crashed by 85.65% to $17868.0 in 2024, then tumbled by 74.38% to $4578.0 in 2025.
  • Its Cash & Current Investments stands at $4578.0 for Q4 2025, versus $69555.0 for Q3 2025 and $1761.0 for Q2 2025.